吉非替尼联合同期胸部放疗治疗不可切除局部晚期EGFR突变NSCLC:WJOG6911L
这项前瞻性单臂研究纳入27例不可切除局部晚期EGFR突变(19外显子缺失或21外显子L858R)NSCLC初治患者,给予吉非替尼250 mg/d持续2年联合同期胸部放疗64 Gy/32次。2年PFS率为29.6%(单侧95%CI 17.6%–),客观缓解率81.5%,中位PFS 18.6个月,中位OS 61.1个月;约半数患者首次复发为孤立脑转移,≥3级不良事件为疲乏、皮肤反应和食欲减退(各3.7%)。结论提示该方案可耐受并可能有效。
要点
- 吉非替尼联合同期胸部放疗在局部晚期EGFR突变NSCLC中可耐受。
- 2年PFS率29.6%,客观缓解率81.5%,中位PFS 18.6个月。
- 约半数患者首次复发为孤立脑转移,需关注颅内监测。
核心结论
- 吉非替尼联合同期胸部放疗在不可切除局部晚期EGFR突变NSCLC中显示可耐受性和可能疗效。
研究设计与样本
- 前瞻性单臂研究,纳入化疗初治的不可切除局部晚期NSCLC伴敏感EGFR突变(19外显子缺失或21外显子L858R)患者28例,可评估27例。
- 治疗方案为吉非替尼250 mg/d持续2年联合同期胸部放疗64 Gy/32次。
- 主要终点为2年无进展生存率。
主要发现
- 独立评审的2年PFS率为29.6%(单侧95%CI 17.6%–)。
- 客观缓解率为81.5%(95%CI 63.3%–91.3%)。
- 中位PFS为18.6个月(95%CI 12.0–24.5个月),中位OS为61.1个月(95%CI 38.1个月–未达到)。
- 约半数患者首次复发部位为孤立脑转移。
- ≥3级不良事件为疲乏、皮肤反应和食欲减退,各占3.7%。
临床怎么用
- 对于不可切除局部晚期EGFR突变NSCLC,可考虑吉非替尼联合同期胸部放疗作为治疗选择。
- 治疗期间需监测并管理疲乏、皮肤反应和食欲减退等不良事件。
- 需关注孤立脑转移作为首次复发模式,考虑相应颅内监测策略。
局限性
- 单臂设计,样本量小(可评估27例),结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit with an immune checkpoint inhibitor in this population. The attempt that introduces EGFR tyrosine kinase inhibitor into the treatment of LA-NSCLC with EGFR mutation has been warranted. METHODS: Chemotherapy-naive patients with unresectable LA-NSCLC with sensitive EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were enrolled. Patients were treated with gefitinib (250 mg/d for 2 y) plus concurrent thoracic radiotherapy (64 Gy/32 fractions). The primary end point was progression-free survival (PFS) at 2 years (trial identifier, UMIN000008366). RESULTS: Between August 2012 and November 2017, a total of 28 patients were enrolled and 27 were eligible. The median age was 67 years (range: 45-74); never/current or former smoker in 15/12 patients, respectively; Eastern Cooperative Oncology Group performance status of 0/1 in 19/8; EGFR exon 19 deletion/exon 21 L858R in 13/14; and c-stage IIIA/IIIB in 14/13. The PFS rate at 2 years by independent review was 29.6% (one-sided 95% confidence interval [CI]: 17.6%-). The overall response rate was 81.5% (95% CI: 63.3%-91.3%), median PFS was 18.6 months (95% CI: 12.0-24.5 mo), and median overall survival was 61.1 months (95% CI: 38.1 mo-not reached). Approximately half of the patients exhibited solitary brain metastasis as their first site of relapse. Adverse events greater than or equal to grade 3 were fatigue, skin reaction, and appetite loss (3.7% each). CONCLUSIONS: This prospective study revealed the tolerability and the possible efficacy of gefitinib plus concurrent thoracic radiotherapy in patients with LA-NSCLC having EGFR mutation.
引用
- Akamatsu H, Murakami H, Harada H, et al. Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. J Thorac Oncol. 2021. PMID: 34116229. doi:10.1016/j.jtho.2021.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。